Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessandro Vannucchi and Paola Guglielmelli.
Alessandro Vannucchi
Connection Strength
1.820
Paola Guglielmelli
  1. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
    View in: PubMed
    Score: 0.961
  2. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
    View in: PubMed
    Score: 0.232
  3. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
    View in: PubMed
    Score: 0.225
  4. The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19. Int J Lab Hematol. 2020 12; 42(6):e270-e273.
    View in: PubMed
    Score: 0.224
  5. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021 12 01; 96(12):1580-1586.
    View in: PubMed
    Score: 0.060
  6. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
    View in: PubMed
    Score: 0.059
  7. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.